Daily Recap - WEDNESDAY
Join panelists Drs. Janet Pope, Richard Conway, Meral El Ramahi and Jack Cush recap the best presentations presented on day four of the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →What's hot
View all perspectives
What's Hot
EXXELERATE Study: Do High RF Titers Impact Response to TNF Inhibitors?
Dr. Jonathan Kay discusses abstract 2148 with Dr. Josef Smolen at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Bimekizumab in Active AS: 5 Year Study
Dr. Atul Deodhar reporting on abstract 0519 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cannabinoid Receptor in RA Patients
Dr. Arthur Kavanaugh discusses abstract 0025 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Treatments in SpA
Dr. Rachel Tate and Dr. Catherine Blakewell discuss treatment options patients in spondyloarthritis at the 2023 ACR Convergence meeting in San Diego, CA. Abstracts discussed include 0520, 0530, 0521 and 0529.
Watch video →
PR3+ in Lupus Nephritis
Dr. Jack Cush discusses abstract 2427 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Simulated Trials to Counter ORAL Survelliance
Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Difficult to Treat axSpA
Dr. Peter Nash reports on abstracts 0514 and 0538 from the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Window of Opportunity in PsA
Dr. Peter Nash discusses a study that looks at the window of opportunity for treatment of PsA at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
TMP SMX Prophylaxis in GPA
Dr. Jack Cush and Dr. Janet Pope discuss abstract 1584 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The FOREMOST Study: Apremilast in PsA
Dr. Peter Nash reports on abstract 1691 presented at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
The SMART Study: Split Dose Oral Methotrexate
Dr. Jack Cush discusses abstract 1583 presented at the 2023 ACR Convergence meeting in San Diego.
Watch video →
Real World Experience with PEXIVAS Low Steroid Taper
Dr. Mike Putman discusses abstract 0725 with Dr. Sophie Nagle at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.
Read more →
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNow's #ACRbest abstract reports from Monday, November 13, 2023 at #ACR23, covering The Great Debate, SGLPT2 inhibitors in SLE, the SMART Study of MTX, TMP/SMX Prophylaxis, RA-ILD & TNF Inhibitors, cancer research and more.
Read more →
Effects of Apremilast on Cardiometabolic Effects in PsA
Dr. Peter Nash discusses abstract 1414 at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
An Interview with Kevin Winthrop: Three Questions About COVID 19
Drs. Jack Cush and Kevin Winthrop discuss COVID 19 at 2023 ACR Convergence in San Diego, CA.
Watch video →
Biologics as First-line Therapy for PMR and GCA?
Dr. Eric Dein talks with Dr. Philip Seo, one of two panelists for the Great Debate: Should PMR and GCA Be Treated with Advanced Therapies at Disease Onset? at the 2023 ACR Convergence meeting in San Diego, CA.
Watch video →
David Liew drdavidliew
2 years ago
Low-grade troponin rises in RA: ignore, or meaningful?
@BrighamWomens RA pts n=329
baseline hs-cTnT
Trops actually predict MACE:
HR 6.62
independent of traditional CV risk, CRP
Traditional CV RF not enough in RA
Maybe smoke does predict future fire?
#ACR23 ABST0387 @RheumNow https://t.co/33ZCgzYIl4
TheDaoIndex KDAO2011
2 years ago
Let’s talk about SEX! >30% of pts wished their rheums asked them about sexual health, >50% pts with sexual dysfunction have RA. The presence of menopause, younger age, and children were assc with sexual dysfunction. presenter Dr D Flores Abstr#0145, #abst#0146 #ACR23 @RheumNow https://t.co/9AdoTtEwFp
David Liew drdavidliew
2 years ago
Patient reported outcomes between clinic visits: worth doing?
RA pts starting ADA/UPA, n=150
ArthritisPower/PatientSpot app for PROs between visits
52% of CDAI change explained by PROs
Maybe a helpful tool in prioritising RA clinic reviews?
@RADoctor #ACR23 ABST0380 @RheumNow https://t.co/oTttAlIxQR
Dr. John Cush RheumNow
2 years ago
RheumNow’s expanded coverage of the #ACR23 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Janet Pope
2 years ago
You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest @ACRheum @RheumNow Pos#L10 https://t.co/DfChrAyslL
Dr. Rachel Tate
2 years ago
PEXIVAS results: the reduced-dose GC regimen associated w/ ^ death, ESRD, and uncontrolled dz risk in severe GPA/MPA pts. Even greater risk in pts w/ creatinine levels > 300 μmol/L & in those tx w/ RTX induction. #ACR23 Plenary 0725 https://t.co/mBMrEaGj5k @rheumnow https://t.co/flAfYEKSXJ
Dr. Rachel Tate
2 years ago
DESIR cohort update in Abs #0513 shows axSpA pt imaging doesn't "worsen" after pregnancy. However, following 1st pregnancy, can see slight increase in L SIJ score, but typically not enough to define "worsening." #ACR23 https://t.co/HaYj3RQGFb @rheumnow https://t.co/5MQCXS1Kat
Dr. Rachel Tate
2 years ago
Acute pregnancy-related CV event risk found to be highest in pts w/ SLE+ APS, followed by primary APS, and SLE w/ LN. Most importantly, 25-30% of events happen post-partum! Monitor these pts carefully! #ACR23 Plenary 0722 #ACRbest https://t.co/yD5VFJ2SXh @rheumnow https://t.co/PDvzbs19fR
TheDaoIndex KDAO2011
2 years ago
Prof Mustelin explains why Basic Science research is important in medicine. New ideas need:
👉discovery
👉explanation
👉 impact
#ACR23 @rheumnow #YearInReview #BasicScience https://t.co/t0W3GdUtWD
Janet Pope
2 years ago
Who knew? VEXAS =cluster of findings from a somatic mutation N=110 studying retention of advanced Rx. #JAKi had far better retention than other #Rx. Although there could be channeling bias, I am impressed! Access for off label is a different issue #L03 #ACR23 @RheumNow @ACRheum https://t.co/RE4BVdZeWt
sheila
2 years ago
Dr. Seo shares an interesting case report on the use of anti-TRBV9 Ab in a patient with AS.
Another potential treatment option for AS?🧐
Something to watch out for in the future.
#ACR23 @RheumNow @rheumarhyme https://t.co/y6mQ756TKK
TheDaoIndex KDAO2011
2 years ago
A new way to die! #Ferroptosis may be a more important means of cell death. It’s an intracellular iron-dependent form of cell death that is distinct from apoptosis, necrosis, and autophagy #ACR23 @rheumnow #YearInReview https://t.co/DB7iuwuWTX https://t.co/v5Z2Od8mJ7
Mike Putman EBRheum
2 years ago
Q&A from RA-ILD Guidelines Presentation:
Q: "Why was AZA recommended but ABA was not?"
A: "The evidence was not as good for it so it was not included"
Can anyone explain this to me? Where is this amazing data for AZA in RA-ILD?
@RheumNow #ACR23
Md Yuzaiful Md Yusof
2 years ago
#ACR23 Year in Review. CAR-T cell showed promising results in #SLE based on case series but extrapolation to other RMD may be challenging.
-Myositis recurred after 7days, needing MMF
-No improvement in lung fibrosis #SSc
Longer-term data & trial data are needed @RheumNow https://t.co/4Zmjvr51Ab
Mike Putman EBRheum
2 years ago
More good data for benralizumab (IL5i) in EGPA, @TerrierBen
There may be additional benefit over MEPO given deeper eosinophil depletion
Checkout our recent editorial about this in @TheLancetRheum
@RheumNow #ACR23 https://t.co/1d2nITOuOs
Poster Hall